Table 2 Validated synergistic drug combinations in NCI-60
From: Integrative network analysis identifies potential targets and drugs for ovarian cancer
Drug 1 | Drug 2 | Target 1 | Target 2 | Score | Cell line |
|---|---|---|---|---|---|
Erlotinib | Dasatinib | EGFR | EPHA2 | 34.44 | IGROV1 |
Gefitinib | Dasatinib | EGFR | EPHA2 | 23.22 | IGROV1 |
Vandetanib | Dasatinib | EGFR | EPHA2 | 18.44 | IGROV1 |
Dasatinib | Tamoxifen | EPHA2 | PRKCZ, PRKCI | 16.78 | IGROV1 |
Lapatinib | Sirolimus | ERBB2, EGFR | MTOR | 14.00 | IGROV1 |
Vandetanib | Everolimus | EGFR | MTOR | 13.56 | IGROV1 |
Celecoxib | Dasatinib | PDPK1 | EPHA2 | 13.11 | IGROV1 |
Lapatinib | Everolimus | ERBB2, EGFR | MTOR | 12.44 | IGROV1 |
Sirolimus | Tamoxifen | MTOR | PRKCZ, PRKCI | 11.67 | IGROV1 |
Lapatinib | Dasatinib | ERBB2, EGFR | EPHA2 | 11.00 | IGROV1 |
Gefitinib | Everolimus | EGFR | MTOR | 10.78 | IGROV1 |
Dasatinib | Imatinib | EPHA2 | PDGFRA | 10.56 | IGROV1 |
Celecoxib | Vandetanib | PDPK1 | EGFR | 9.11 | IGROV1 |
Sirolimus | Vandetanib | MTOR | EGFR | 8.78 | IGROV1 |
Erlotinib | Tamoxifen | EGFR | PRKCZ, PRKCI | 8.33 | IGROV1 |
Dasatinib | Tamoxifen | EPHA2 | PRKCZ, PRKCI | 11.33 | OVCAR-3 |
Sirolimus | Everolimus | MTOR | MTOR | 9.56 | OVCAR-3 |
Celecoxib | Dasatinib | PDPK1 | EPHA2 | 9.44 | OVCAR-3 |
Thalidomide | Dasatinib | TNF | EPHA2 | 8.89 | OVCAR-3 |
Sirolimus | Gefitinib | MTOR | EGFR | 10.56 | OVCAR-4 |
Gefitinib | Everolimus | EGFR | MTOR | 9.44 | OVCAR-4 |
Lapatinib | Sirolimus | ERBB2, EGFR | MTOR | 9.44 | OVCAR-4 |
Vandetanib | Tamoxifen | EGFR | PRKCZ, PRKCI | 9.33 | OVCAR-5 |
Dasatinib | Tamoxifen | EPHA2 | PRKCZ, PRKCI | 14.78 | SK-OV-3 |
Everolimus | Tamoxifen | MTOR | PRKCZ, PRKCI | 11.78 | SK-OV-3 |
Lapatinib | Dasatinib | ERBB2, EGFR | EPHA2 | 10.11 | SK-OV-3 |
Celecoxib | Dasatinib | PDPK1 | EPHA2 | 9.56 | SK-OV-3 |
Gefitinib | Dasatinib | EGFR | EPHA2 | 9.11 | SK-OV-3 |